Credit Suisse Group AG announced Clovis Oncology Inc (NASDAQ:CLVS), bumping up its stock price target to $41.00 earlier today
- Updated: September 25, 2016
Clovis Oncology Inc (NASDAQ:CLVS) had its price target upped to $41.00 by Credit Suisse Group AG in a report released 09/21/2016. The updated stock price target implies a potential upside of 0.18% from the company's most recent close.
On 8/24/2016, Mizuho Securities released a statement about Clovis Oncology Inc (NASDAQ:CLVS) raised the target price from $15.00 to $23.00. At the time, this indicated a possible downside of 0.00%.
Displaying a price of $34.83, Clovis Oncology Inc (NASDAQ:CLVS) traded -3.18% lower on the day. With the last stock price close up 111.60% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of $24.12 and a 200-day moving average of $17.55. 8,169,572 shares of Clovis Oncology Inc exchanged hands, up from an avg. volume of 2,669,770
See Chart Below
With a total market value of $0, Clovis Oncology Inc has one year low of $11.57 and a one year high of $109.18 .
A total of 8 brokers have issued a research note on the stock. Two analysts rating the company a strong buy, zero brokerages rating the stock a buy, 6 firms rating the stock a hold, 0 brokers rating the stock a underperform, and finally zero firms rating the stock a sell with a consensus target price of $17.50.
Brief Synopsis On Clovis Oncology Inc (NASDAQ:CLVS)
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.